{"id":499871,"date":"2021-06-02T07:34:16","date_gmt":"2021-06-02T11:34:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\/"},"modified":"2021-06-02T07:34:16","modified_gmt":"2021-06-02T11:34:16","slug":"world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\/","title":{"rendered":"World Health Organization Authorizes SINOVAC\u2019s CoronaVac\u00ae for Emergency Use"},"content":{"rendered":"

<\/p>\n

World Health Organization Authorizes SINOVAC\u2019s CoronaVac\u00ae<\/sup> for Emergency Use<\/b><\/p>\n

BEIJING–(BUSINESS WIRE<\/a>)–
\nSINOVAC Biotech Ltd. (\u201cSINOVAC\u201d or the \u201cCompany\u201d) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that CoronaVac\u00ae, an innovative, inactivated coronavirus vaccine developed by SINOVAC Life Sciences Co., Ltd. (\u201cSINOVAC\u201d), a subsidiary of the Company, was approved for emergency use under the World Health Organization (\u201cWHO\u201d) Emergency Use Listing (\u201cEUL\u201d) procedure. Prior to this, the Strategic Advisory Group of Experts on Immunization (\u201cSAGE\u201d) had recommended CoronaVac\u00ae for use in adults 18 years and older in a two-dose schedule with an interval of 2 to 4 weeks.\n<\/p>\n

\nThe WHO EUL procedure is a technical review process to assess and review unlicensed vaccines and other products to expedite their availability to people affected by public health emergencies. SINOVAC had submitted clinical and non-clinical research data, as well as manufacturing and control (\u201cCMC\u201d) data, to the WHO review group to evaluate the quality, safety, efficacy data and risk management plan of CoronaVac\u00ae. In February 2021, the WHO conducted an on-site inspection of SINOVAC\u2019s manufacturing facilities of CoronaVac\u00ae, as well as its quality management system. SAGE also conducted a systematic review of CoronaVac\u00ae and concluded that the benefits of using SINOVAC\u2019s inactivated coronavirus vaccine are greater than the known risks, recommending the use of this vaccine.\n<\/p>\n

\nIn addition, the European Medicine Agency (\u201cEMA\u201d) has initiated the rolling review of CoronaVac\u00ae. This marks the first step in the process for CoronaVac\u00ae to obtain EU approval for use.\n<\/p>\n

\nMr. Weidong Yin, the Chairman, President, and CEO of SINOVAC, said, \u201cThe phase III clinical research and follow-up real-world studies in Brazil, Turkey, Indonesia and Chile represent good examples of the collaborative, global action against the pandemic. These studies have provided a solid scientific foundation for CoronaVac\u00ae to be approved by more than 40 countries, as well as the WHO. These achievements could not have happened without the efforts of global partners and scientists. As the COVID-19 pandemic persists, SINOVAC will continue to participate in pandemic prevention and control actions, acknowledging the value of China’s COVID-19 vaccine as a global public good and contributing to the international triumph over the COVID-19 pandemic.\n<\/p>\n

\nIn June 2020, CoronaVac\u00ae became the first vaccine approved for emergency use in China and was further approved for conditional marketing use on February 5th, 2021.\n<\/p>\n

\nOn April 1st, 2021, the third phase of a CoronaVac\u00ae bulk production manufacturing facility was completed and began operations, allowing the annual production capacity to exceed 2 billion doses. SINOVAC’s manufacturing control system of CoronaVac\u00ae has been inspected by China, Brazil, Indonesia, Chile and Saudi Arabia, as well as the WHO. Large-scale production of hundreds of batches have proven the stability and reliability of SINOVAC\u2019s vaccine manufacturing control system. At this time, SINOVAC has provided CoronaVac\u00ae to nearly 40 countries and regions, including mainland China, directly and indirectly. The total supply has already exceeded 600 million doses. Moreover, according to incomplete statistics, over 430 million doses have been administrated worldwide. SINOVAC has become the largest domestic supplier and exporter of China\u2019s COVID-19 vaccine. The safety and effectiveness of CoronaVac\u00ae has been verified all over the world.\n<\/p>\n

\nAbout SINOVAC\n<\/p>\n

\nSINOVAC Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus71 (EV71), hepatitis A and B, seasonal influenza, 23-Valent pneumococcal polysaccharide (\u201cPPV\u201d), H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella and mumps. SINOVAC\u2019s COVID-19 vaccine, CoronaVac\u00ae, has been granted emergency use approval or conditional marketing authorization by over 40 countries or regions worldwide. Healive\u00ae, the hepatitis A vaccine manufactured by the Company, has passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, an innovative vaccine developed by SINOVAC against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, SINOVAC was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government’s vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. The Company is developing several new products including a Sabin-strain inactivated polio vaccine and combined vaccines. SINOVAC primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company is seeking market authorization of its products in over 30 countries outside of China. For more information please see the Company\u2019s website at www.sinovac.com<\/a>.\n<\/p>\n

\nSafe Harbor Statement\n<\/p>\n

\nThis press release may include certain statements that are not descriptions of historical facts, but are forward-looking statements. These statements are made under the \u201csafe harbor\u201d provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as \u201cwill,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cfuture,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cbelieves,\u201d \u201cestimates\u201d and similar statements. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results to differ materially from those contained in any such statements. In particular, the outcome of any litigation is uncertain, and the Company cannot predict the potential results of the litigation it filed or filed against it by others. Additionally, the triggering of a shareholder rights plan is nearly unprecedented, and the Company cannot predict the impact on the Company or its stock price as a result of the trigger of the rights plan.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210602005422\/en\/<\/a><\/span><\/p>\n

\nSINOVAC Biotech Ltd.
\n
Helen Yang
\n
Tel: +86-10-8279-9871 or
\n
+86-10-5693-1897
\n
Fax: +86-10-6296-6910
\n
Email: ir@sinovac.com<\/a><\/p>\n

\nICR Inc.
\n
Bill Zima
\n
U.S.: 1-646-308-1707
\n
Email: william.zima@icrinc.com<\/a><\/p>\n

KEYWORDS:<\/b> China Asia Pacific<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research Medical Devices Medical Supplies Infectious Diseases Biotechnology Health Pharmaceutical Other Science Science<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

World Health Organization Authorizes SINOVAC\u2019s CoronaVac\u00ae for Emergency Use BEIJING–(BUSINESS WIRE)– SINOVAC Biotech Ltd. (\u201cSINOVAC\u201d or the \u201cCompany\u201d) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that CoronaVac\u00ae, an innovative, inactivated coronavirus vaccine developed by SINOVAC Life Sciences Co., Ltd. (\u201cSINOVAC\u201d), a subsidiary of the Company, was approved for emergency use under the World Health Organization (\u201cWHO\u201d) Emergency Use Listing (\u201cEUL\u201d) procedure. Prior to this, the Strategic Advisory Group of Experts on Immunization (\u201cSAGE\u201d) had recommended CoronaVac\u00ae for use in adults 18 years and older in a two-dose schedule with an interval of 2 to 4 weeks. The WHO EUL procedure is a technical review process to assess and review unlicensed vaccines and other products to … <\/p>\n

Continue reading “World Health Organization Authorizes SINOVAC\u2019s CoronaVac\u00ae for Emergency Use”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-499871","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nWorld Health Organization Authorizes SINOVAC\u2019s CoronaVac\u00ae for Emergency Use - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"World Health Organization Authorizes SINOVAC\u2019s CoronaVac\u00ae for Emergency Use - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"World Health Organization Authorizes SINOVAC\u2019s CoronaVac\u00ae for Emergency Use BEIJING–(BUSINESS WIRE)– SINOVAC Biotech Ltd. (\u201cSINOVAC\u201d or the \u201cCompany\u201d) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that CoronaVac\u00ae, an innovative, inactivated coronavirus vaccine developed by SINOVAC Life Sciences Co., Ltd. (\u201cSINOVAC\u201d), a subsidiary of the Company, was approved for emergency use under the World Health Organization (\u201cWHO\u201d) Emergency Use Listing (\u201cEUL\u201d) procedure. Prior to this, the Strategic Advisory Group of Experts on Immunization (\u201cSAGE\u201d) had recommended CoronaVac\u00ae for use in adults 18 years and older in a two-dose schedule with an interval of 2 to 4 weeks. The WHO EUL procedure is a technical review process to assess and review unlicensed vaccines and other products to … Continue reading "World Health Organization Authorizes SINOVAC\u2019s CoronaVac\u00ae for Emergency Use"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-02T11:34:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210602005422r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"World Health Organization Authorizes SINOVAC\u2019s CoronaVac\u00ae for Emergency Use\",\"datePublished\":\"2021-06-02T11:34:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\\\/\"},\"wordCount\":970,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210602005422r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\\\/\",\"name\":\"World Health Organization Authorizes SINOVAC\u2019s CoronaVac\u00ae for Emergency Use - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210602005422r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-06-02T11:34:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210602005422r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210602005422r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"World Health Organization Authorizes SINOVAC\u2019s CoronaVac\u00ae for Emergency Use\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"World Health Organization Authorizes SINOVAC\u2019s CoronaVac\u00ae for Emergency Use - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\/","og_locale":"en_US","og_type":"article","og_title":"World Health Organization Authorizes SINOVAC\u2019s CoronaVac\u00ae for Emergency Use - Market Newsdesk","og_description":"World Health Organization Authorizes SINOVAC\u2019s CoronaVac\u00ae for Emergency Use BEIJING–(BUSINESS WIRE)– SINOVAC Biotech Ltd. (\u201cSINOVAC\u201d or the \u201cCompany\u201d) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that CoronaVac\u00ae, an innovative, inactivated coronavirus vaccine developed by SINOVAC Life Sciences Co., Ltd. (\u201cSINOVAC\u201d), a subsidiary of the Company, was approved for emergency use under the World Health Organization (\u201cWHO\u201d) Emergency Use Listing (\u201cEUL\u201d) procedure. Prior to this, the Strategic Advisory Group of Experts on Immunization (\u201cSAGE\u201d) had recommended CoronaVac\u00ae for use in adults 18 years and older in a two-dose schedule with an interval of 2 to 4 weeks. The WHO EUL procedure is a technical review process to assess and review unlicensed vaccines and other products to … Continue reading \"World Health Organization Authorizes SINOVAC\u2019s CoronaVac\u00ae for Emergency Use\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-02T11:34:16+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210602005422r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"World Health Organization Authorizes SINOVAC\u2019s CoronaVac\u00ae for Emergency Use","datePublished":"2021-06-02T11:34:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\/"},"wordCount":970,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210602005422r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\/","name":"World Health Organization Authorizes SINOVAC\u2019s CoronaVac\u00ae for Emergency Use - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210602005422r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-06-02T11:34:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210602005422r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210602005422r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/world-health-organization-authorizes-sinovacs-coronavac-for-emergency-use\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"World Health Organization Authorizes SINOVAC\u2019s CoronaVac\u00ae for Emergency Use"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499871","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=499871"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499871\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=499871"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=499871"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=499871"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}